DGAP-News: CEVEC grants license to Biotest AG for production of tailor-made glycoproteins


DGAP-News: CEVEC Pharmaceuticals GmbH / Key word(s): Contract
CEVEC grants license to Biotest AG for production of tailor-made
glycoproteins

01.07.2015 / 08:31

---------------------------------------------------------------------

Press Release

CEVEC grants license to Biotest AG for production of tailor-made
glycoproteins

Cologne, Germany, July 1st, 2015 - CEVEC Pharmaceuticals GmbH (CEVEC), an
expert for the production of glyco-optimized biopharmaceuticals, today
announced that it has granted a license for its proprietary CAP(R)Go
technology to Biotest AG for the development, production and
commercialization of candidate molecules to treat the symptoms of
hemophilia patients.

Under the terms of the license agreement, CEVEC will receive service fees
for ongoing development support, upfront and milestone payments as well as
royalties on future product sales.

"With Biotest, we have found an important partner for our unique CAP(R)Go
expression system," commented Frank Ubags, Chief Executive Officer of CEVEC
Pharmaceuticals GmbH. "We consider Biotest's commitment as a significant
endorsement of our CAP(R) Go technology."

About Biotest

Biotest AG is a provider of plasma proteins and biological drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
clinical immunology, hematology and intensive medicine. Biotest develops
and markets immunoglobulins, coagulation factors and albumins based on
human blood plasma. These are used for diseases of the immune and
hematopoietic systems. In addition Biotest develops monoclonal antibodies
in the indications of rheumatoid arthritis and cancer of plasma cells,
which are produced by recombinant technologies. Biotest has more than 2.100
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.

About CEVEC:

Privately held CEVEC is an expert for the production of tailor-made
recombinant glyco-proteins and gene therapy vectors based in Cologne,
Germany. The Company's technologies, CAP(R)Go and CAP(R)GT are based on a
unique human cell expression system.

The CAP(R)Go expression platform comprises a portfolio of glyco-optimized
human suspension cell lines for tailor-made glycosylation of recombinant
proteins. The cells are highly efficient for the production of a broad
range of difficult to express glycoproteins and provide authentic human
post-translational modifications. CAP(R)Go has proven to enhance the
activity, stability and serum half-life of several candidate proteins.

The CAP(R)GT expression platform provides a fully scalable, regulatory
endorsed production system for gene therapy vectors. CAP(R)GT cells grow to
high cell densities show a broad viral propagation spectrum including
lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV).
Furthermore, CAP(R)GT enables easier scale-up and reduced production costs
when compared to adherent cell culture systems.

Research collaborations with international pharmaceutical and biotechnology
partners followed by licensing agreements for the technology forms one
revenue base for CEVEC. In addition, the Company provides contract
manufacturing for the cGMP production in CAP(R)Go and CAP(R)GT cells.

Contact:      

<pre>

CEVEC Pharmaceuticals GmbH                 MC Services AG
Frank Ubags                                Anne Hennecke
Chief Executive Officer                    Public Relations
T.:+49 221 460 20 800                      T.: +49 211 529 252 22
E.: ubags@cevec.com                        E.: anne.hennecke@mc-services.eu


</pre>



---------------------------------------------------------------------

01.07.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


373813 01.07.2015